SuperworthAlto Neuroscience shares outstanding ANRO
Diluted shares outstanding, averaged over each quarter, from 2023.
- Latest quarter, to Jun 30, 2026
- 42.8M
- On a year earlier
- +58.1%
- more shares
Alto Neuroscience had 42.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 58.1% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 34.1M | +28% |
| FY2024 | 26.8M | +609% |
| FY2023 | 3.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 42.8M | +58% | |
| Q1 FY26 | 32.9M | +22% | |
| Q4 FY25 | 34.1M | +28% | |
| Q3 FY25 | 27.1M | +1% | |
| Q2 FY25 | 27.1M | +1% | |
| Q1 FY25 | 27M | +54% | |
| Q4 FY24 | 26.8M | +609% | |
| Q3 FY24 | 27M | +620% | |
| Q2 FY24 | 26.9M | +624% | |
| Q1 FY24 | 17.6M | +377% | |
| Q4 FY23 | 3.8M | n/a | |
| Q3 FY23 | 3.7M | n/a |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Alto Neuroscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.